David Hyun, MD

The reality of the COVID-19 pandemic will force lawmakers to firmly act on behalf of antibiotic policies, according to an expert with Pew Charitable Trusts.

Despite significant concerns from many oncologists regarding the effects of drug resistant bacteria, many pharmaceutical companies have recently stopped developing antibiotics.